Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trialRobert D. Little, Miles Sparrow, Ashish Srinivasan et al.|BMJ Open|2024Cited by 5